Influenza virus continues to cause significant morbidity and mortality despite the fact that both anti-influenza viral drugs and vaccines to the current circulating strains are available [1, 2]. In terms of anti-influenza drug development, the surface-oriented viral enzyme sialidase (neuraminidase, NA), which plays a major role in the virus life cycle by facilitating release of virus progeny from the infected cell , has proven a successful target for the development of clinically useful drugs [4, 5]. Potent and selective inhibitors of the viral sialidase, such as zanamivir (1, Relenza) and oseltamivir carboxylate (OC, 2; the active form of oseltamivir 3, Tamiflu), the two widely used anti-influenza drugs, efficiently block viral sialidase activity resulting in virus progeny remaining clumped at the infected cell’s surface  and, consequently, limitation of the spread of infection. The phenomenon of resistance development to drugs-in-use, however, is a continuing issue , and applies to both zanamivir and oseltamivir. Oseltamivir, the most used anti-influenza drug, has suffered significant loss of efficacy as a result of drug resistance during the past 4 years .
Virus Progeny Virus Life Cycle Virus Group Oseltamivir Carboxylate Sialidase Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM et al (2010) Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 85:381–388CrossRefPubMedGoogle Scholar
Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature (Lond) 443:45–49CrossRefGoogle Scholar
Amaro RE, Minh DDL, Cheng LS, Lindstrom WM Jr, Olson AJ, Lin J-H, Li WW, McCammon JA (2007) Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 129:7764–7765CrossRefPubMedGoogle Scholar
Dyason JC, von Itzstein M (2012) Influenza virus sialidase and structure-based drug design. In: von Itzstein M (ed) Influenza virus sialidase: a drug discovery target. Springer, Basel, pp 67–75CrossRefGoogle Scholar
Wen W-H, Wang S-Y, Tsai K-C, Cheng Y-SE, Yang A-S, Fang J-M, Wong C-H (2010) Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses. Bioorg Med Chem 18:4074–4084CrossRefPubMedGoogle Scholar
Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS et al (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1:113CrossRefPubMedGoogle Scholar
Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM (2010) Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J Med Chem 53:7377–7391CrossRefPubMedGoogle Scholar
Holzer CT, von Itzstein M, Jin B, Pegg MS, Stewart WP, Wu WY (1993) Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconj J 10:40–44CrossRefPubMedGoogle Scholar
Okamoto K, Kondo T, Goto T (1987) Synthetic studies on gangliosides. 2. Functionalization of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid methyl ester. Bull Chem Soc Jpn 60:631–636CrossRefGoogle Scholar
Paulsen H, Matschulat P (1991) Synthese von C-Glycosiden der N-Acetylneuraminsäure und weiteren Derivaten. Liebigs Ann Chem 5:487–495CrossRefGoogle Scholar
Nolan SP, Clavier H (2010) Chemoselective olefin metathesis transformations mediated by ruthenium complexes. Chem Soc Rev 39:3305–3316CrossRefPubMedGoogle Scholar
Scholl M, Ding S, Lee CW, Grubbs RH (1999) Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. Org Lett 1:953–956CrossRefPubMedGoogle Scholar
Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Véron M, van der Werf S, Naffakh N (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50:3809–3815CrossRefPubMedGoogle Scholar
Hartshorn MJ (2002) AstexViewer: a visualisation aid for structure-based drug design. J Comput Aided Mol Des 16:871–881CrossRefPubMedGoogle Scholar